
The U.S. Food and Drug Administration (FDA) has extended its review period by three months for Provention Bio’s (NASDAQ:PRVB) Biologics License Application (BLA) for teplizumab in patients with type 1 diabetes.
The regulatory agency has set a new target action goal date of November 17, 2022.